The primary concern relates to aspiration risk
The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is a liquid solution comprising an aqueous mixture of semaglutide, or a pharmaceutically acceptable salt, a permeation enhancer, a bioadhesive agent, a solubilising agent, a buffering agent, a chelator, a tonicity agent, and a preservative
AOD-9604 is a 16-amino-acid synthetic peptide
Research suggests that semaglutide, on insulin signaling, might disrupt the regulation of the HPA axis, neurotrophic factors, and neurotransmitters involved in depression and other mental health conditions